In particular, prostate cancer, gastrointestinal stromal tumor, malignant mesothelioma, and papillary thyroid cancer were found to be potential targets for TACTICs therapy, as all representative specimens showed VEGFR2-positive tumor vessels. The gene discussed is KDR; the disease is prostate cancer.